WO2002011704A2 - Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases - Google Patents
Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases Download PDFInfo
- Publication number
- WO2002011704A2 WO2002011704A2 PCT/EP2001/008676 EP0108676W WO0211704A2 WO 2002011704 A2 WO2002011704 A2 WO 2002011704A2 EP 0108676 W EP0108676 W EP 0108676W WO 0211704 A2 WO0211704 A2 WO 0211704A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diphosphonate
- butyl
- tert
- ethenylidene
- hydroxy
- Prior art date
Links
- 0 Cc(cc1I)c(*)c(N)c1O* Chemical compound Cc(cc1I)c(*)c(N)c1O* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
Definitions
- the present invention relates to the use of diphosphonate compounds in the treatment or prevention of bone diseases such as osteoporosis, and in particular those bone diseases requiring bone anabolic activity.
- diphosphonate ester and “bisphosphonate ester”, respectively “diphosphonic acid” and “bisphosphonic acid” will be used interchangeably; the terms “diphosphonate ester” and “diphosphonic acid” being an older terminology which however is still widely used.
- Osteoporosis is caused by an imbalance between bone formation and bone , resorption, resulting in bone loss and fractures. Osteoporosis represents a major public health problem and it is estimated that one out of two women who have reached the age of 50 will sustain an osteoporotic fracture during her remaining life.
- the bisphosphonic acids also diphosphonic acids
- their salts are a class of compounds which decrease the activity of the bone resorbing cells (osteoclasts); they are cytotoxic to the osteoclasts and prevent bone destruction by this mechanism. They do not affect the activity of the bone forming cells.
- Anti-resorptive bisphosphonic acids are currently used for the treatment of various bone diseases such as osteoporosis, hypercalcemia due to malignancies and inhibition of tumor cell metastasis in bone tissue. Despite their proven pharmacological efficacy, the clinical utility of the bisphosphonic acids is limited by their very low oral bioavailibility and their gastrointestinal toxicity.
- the ideal treatment for the prevention and the treatment of bone diseases would be to increase bone formation by stimulating the bone forming cells (osteoblasts).
- the large majority of therapeutic agents which stimulate bone formation or inhibit bone turnover are hormones or derivatives of hormones (estrogens, anabolic steroids, calcitonin, parathyroid hormone, vitamin D) with numerous side effects which can be expected from their hormonal activities.
- Sodium fluoride, the old prophylactic agent for dental caries, is still the most widely used compound for the stimulation of bone formation. There is thus a need for new orally active compounds that act by stimulating bone formation (bone anabolic drugs).
- US Patent N° 5,043,330 and US Patent N° 5,204,336 each discloses a class of aryl-substituted diphosphonate esters falling within the general formula (I) set out below. The compounds are stated to be potential lipid lowering agents. US Patent No. 6,127,350 further states that a subgroup of compounds within formula (I) are potential antineoplastic agents.
- diphosphonate_compounds of the formula (I) as set out below have bone anabolic activity. Furthermore, contrary to the diphosphonic acids and salts previously used in the treatment of bone diseases, diphosphonate esters of the formula (I) below have a high oral bioavailability.
- the diphosphonate esters of the formula (I) are not competitive inhibitors of HMGCoA reductase but exert a hypocholesterolemic activity by increasing the rate of HMGCoA reductase degradation. The resulting decrease in cholesterol and in isoprenoid synthesis triggers an increase in the activity of the bone forming cells.
- the bisphosphonate esters of the invention are useful for the treatment of diseases of bone metabolism such as osteoroposis.
- the diphosphonate compounds of the formula (I), and in particular diphosphonate esters, have been found to increase bone formation in treated mice.
- the bone anabolic activity of the compounds of the present invention is clearly demonstrated by the increase in the number of bone forming osteoblasts, increase in bone weight and in calcium and phosphorus concentration, as compared to the respective parameters of the control group. Because'of the coordinative nature of the regulation of bone formation and bone resorbtion, an increase in osteoblastic activity will lead to a decrease in osteoclastic bone resorbtion.
- the favourable pharmacological property of the diphosphonate esters of the formula (I) is due to their inhibitory activity of the mevalonate/isoprenoid/cholesterol synthetic pathway since these bisphosphonate esters increase the rate of degradation of HMGCoA reductase.
- This mechanism of action is comparable to the recently demonstrated bone anabolic activity of the inhibitors of HMGCoA reductase, the so called statins, see for instance: Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G "Stimulation of bone formation in vitro and in rodents by statins" Science 1999, 286:1946-1949.
- the diphosphonate esters of the formula (I) display a remarkable systemic bioavailability compared to both the inhibitors of HMGCoA reductase and the classical bisphosphonic acids.
- the diphosphonate esters of this invention can be administered orally, intradermally and locally; which represents an advantage over bisphosphonic acids from the prior art which need to be given by injection due to their poor cell penetration that results from their ionic chemical structures.
- the compounds of the formula (I) are thus useful for the treatment (or prevention) of diseases involving bone tissue such as:
- bone loss associated with cancer therapies e.g., bone loss associated with the treatment of gonadotropin-releasing hormone agonists for prostate cancer and bone loss associated with chemotherapy for breast cancer, wherein ' such chemotherapy includes, but is not limited to, cyclophosphamide, methotrexate, fiuorouracil, paclitaxel, doxorubicin, tamoxifen and combinations thereof
- chemotherapy includes, but is not limited to, cyclophosphamide, methotrexate, fiuorouracil, paclitaxel, doxorubicin, tamoxifen and combinations thereof
- prevention and treatment of bone loss in HIV patients associated with lipodystrophy and treatment with antiviral drugs e.g., bone loss associated with the treatment of gonadotropin-releasing hormone agonists for prostate cancer and bone loss associated with chemotherapy for breast cancer, wherein ' such chemotherapy includes, but is not limited to, cyclophosphamide, methotrexate, fiuorouracil, pac
- the invention provides the use of a compound for the manufacture of a medicament for the prevention or treatment of bone diseases and/or for increasing bone formation, said compound having the formula (I): where:
- - ⁇ 0 is H, or an alkyl group having from 1 to 4 carbon atoms; ⁇ , 3 - X , X and X are identical or different and are H, a straight or branched alkyl or alkoxy group having from 1 to 8 carbon atoms,
- - X 4 is H, a straight or branched alkyl group having from 1 to 8 carbon atoms, or an optionally substituted benzyl group,
- - X 5 is H, or a straight or branched alkyl group having from 1 to 8 carbon atoms
- - X 6 is H or an alkyl group having from 1 to 4 carbon atoms
- Rl, R2, R3 and R ⁇ are identical or different and are H, a straight, branched or cyclic alkyl group comprising from 1 to 8 carbon atoms, or Rl, R2 and R ⁇ and R4 may form an alkylidenedioxy ring comprising from 2 to 8 carbon atoms
- - L is -CHK ⁇ -CH2-, -(CH 2 ) n -, -O(CH 2 ) n -, -S-, -SO 2 -, -S(CH 2 ) n -, -SO 2 (CH 2 ) n , where n is an integer from 1 to 7, or together with B, L is (CH ⁇ H ⁇ CH ⁇ -CH ⁇ where k is 0 or 1 and d is an integer from 0 to 4,
- (CH 2 )d-CH where k and d are as described above, and with the further proviso that when L is -(CH 2 ) n or -S-, at least one of R 1 , R 2 , R 3 and R 4 is other than hydrogen.
- a compound of the formula (I) as hereinbefore defined provided that when L is other than where k is 0 or 1 and d is an integer from 0 to 4, at least one of Rl, R2, R3 and R ⁇ is other than hydrogen.
- At least one of R 1 , R 2 , R 3 and R 4 can be a straight, branched or cyclic alkyl group having from 1 to 8 carbon atoms.
- at least two, more preferably at least three, and most preferably all four of the groups R 1 , R 2 , R and R 4 are straight, branched or cyclic alkyl groups having from 1 to 8 carbon atoms.
- the invention provides the use of a compound of formula (I) as hereinbefore defined for the manufacture of a medicament for the prevention and treatment of osteoporosis and Paget's disease, e.g. by increasing bone formation.
- the invention provides the use of a compound of the formula (I) as hereinbefore defined for the manufacture of a medicament for the prevention and treatment of bone diseases due to cancer metastasis, for example osteolytic and osteoplastic bone metastasis or tumoral osteolysis, e.g. by increasing bone formation.
- cancer metastasis for example osteolytic and osteoplastic bone metastasis or tumoral osteolysis, e.g. by increasing bone formation.
- the invention provides the use of a compound of the formula (I) as hereinbefore defined for the manufacture of a medicament for the prevention and treatment of conditions due to hypercalcemia, for example calcification of soft tissues (eg kidneys and other organs), or calcification of surgical implants, calcification of arteries due to late stage atherosclerosis.
- hypercalcemia for example calcification of soft tissues (eg kidneys and other organs), or calcification of surgical implants, calcification of arteries due to late stage atherosclerosis.
- the invention provides a method of prevention and/or treatment of a bone disease, which method comprises administering to a patient at risk of or suffering from said disease, an effective (preferably non-toxic) preventive or ⁇ therapeutic amount of a compound of the formula (I) as hereinbefore defined.
- the aforementioned method of treatment of a bone disease further comprises administering, in combination with an effective amount of a compound of the formula (I), an effective amount of a bone resorption inhibitor.
- Such bone resorption inhibitors comprise the following classes of compounds: bisphosphonic acids, such as alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandronic acid, and S- 12911; selective estrogen receptor modulators (SERMs), such as: raloxifene; HMG CoA reductase inhibitors, such as simvastatin, atorvastatin and cerivastatin; steroid hormones, such as Nitamin D; and polypeptide hormones, such as calcitonin.
- bisphosphonic acids such as alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandro
- the invention provides pharmaceutical compositions comprising an amount of a compound of formula (I) as hereinbefore defined effective to stimulate bone formation in a patient in need of such treatment and a pharmaceutically acceptable carrier.
- the pharmaceutical composition is an oral pharmaceutical compositions comprising an amount of a compound of formula (I) as hereinbefore defined effective to stimulate bone formation in a patient in need of such treatment and a pharmaceutically acceptable carrier.
- examples of A include:
- groups X include hydrogen, C ⁇ _4 alkyl; the preferred definition of X being hydrogen.
- groups X , X and X include hydrogen, straight or branched alkyl groups and alkoxy groups having from 1 to 5 carbon atoms, more particularly from 1 to 4 carbon atoms.
- Preferred groups X and X 2 are methyl, ethyl, n-propyl, isopropyl, sec-butyl, tert-butyl, methoxy and ethoxy groups, a particularly preferred group being tert-butyl.
- the preferred definition of X 3 is hydrogen and the preferred definitions of both X 1 and X 2 are tert-butyl.
- Examples of X 4 are H and alkyl groups such as methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl and nonyl.
- Examples of optionally substituted phenylalkyl groups X 4 include optionally substituted benzyl, phenethyl and phenylpropyl groups.
- phenylalkyl groups examples include alkyl groups, alkoxy and alkylthio groups, halogens such as fluoro, chloro, bromo and iodo, hydroxy, thio, amino and mono- and di-alkylamino groups and their amide (in the case of unsubstituted and monoalkylamino groups) derivatives, nitro, alkylsulphonyl, trifluoromethyl and alkoxycarbonyl groups.
- halogens such as fluoro, chloro, bromo and iodo, hydroxy, thio, amino and mono- and di-alkylamino groups and their amide (in the case of unsubstituted and monoalkylamino groups) derivatives, nitro, alkylsulphonyl, trifluoromethyl and alkoxycarbonyl groups.
- R , TKX, R 3 and R ⁇ examples include hydrogen, methyl, ethyl, n- propyl, isopropyl, n-butyl, sec-butyl and tert-butyl.
- the preferred definitions of R 1 , R 2 , R 3 and R 4 are ethyl and isopropyl.
- compounds of formula (I) are su ⁇ risingly effective for increasing bone formation and thus are useful in diseases of bone metabolism.
- the compounds of formula (I) include the alkylidene-diphosphonates (la) and the alkenylidene-diphosphonates (lb).
- Compounds of structure (la) include, for example, those in which: - ⁇ 0 is H, an alkyl group having from 1 to 4 carbon atoms; 1 2 3
- - X ,X and X are identical or different and are H, a straight or branched alkyl or alkoxy group having from 1 to 8 carbon atoms,
- - X 4 is H, a straight or branched alkyl group having from 1 to 8 carbon atoms, an optionally substituted benzyl group
- - X 5 is H, a straight or branched alkyl group having from 1 to 8 carbon atoms
- - X 6 is H or an alkyl group having from 1 to 4 carbon atoms, - q is O or l,
- R3 and R ⁇ are identical or different and are H, a straight, branched or cyclic alkyl group comprising from 1 to 8 carbon atoms, R*, R2 and R3 and R ⁇ may form an alkylidenedioxy ring comprising from 2 to 8 carbon atoms,
- - L is -CH-CH-CH 2 -, -(CH 2 )n-, -O(CH 2 ) n -, -S-, -SO 2 -, -S(CH 2 ) n -, -SO 2 (CH 2 ) n , where n is an integer from 1 to 7,
- - B is H, an alkyl group having from 1 to 4 carbon atoms.
- Compounds of structure (Ib) include, for example, those in which:
- ⁇ - ⁇ 0 is H, an alkyl group having from 1 to 4 carbon atoms;
- - X , X 2 and X are identical or different and are H, a straight or branched alkyl or alkoxy group having from 1 to 8 carbon atoms, - X 4 is H, a straight or branched alkyl group having from 1 to 8 carbon atoms, an optionally substituted benzyl group,
- - X 5 is H, a straight or branched alkyl group having from 1 to 8 carbon atoms,
- - X 6 is H or an alkyl group having from 1 to 4 carbon atoms, - q is O or 1,
- R1, R2, R3 and R ⁇ are identical or different and are H, a straight, branched or cyclic alkyl group comprising from 1 to 8 carbon atoms, R*, R 2 and R 3 and R ⁇ may form an alkylidenedioxy ring comprising from 2 to 8 carbon atoms,
- - k is zero or 1 and d is zero to 4.
- - ⁇ 0 is H, an alkyl group having from 1 to 4 carbon atoms; i 2 3 - X .
- X and X are identical or different and are H, a straight or branched alkyl or alkoxy grqup having from 1 to 8 carbon atoms, may be prepared in accordance with the procedures described in the US Patent N°
- - ⁇ 0 is H, an alkyl group having from 1 to 4 carbon atoms;
- - X 4 is H, a straight or branched alkyl group having from 1 to 8 carbon atoms,
- - X 5 is H, a straight or branched alkyl group from 1 to 8 carbon atoms,
- - X 6 is H or an alkyl group from 1 to 4 carbon atoms
- the compounds of formula (I) can be administered by any of a variety of routes.
- they can be administered orally, or by delivery across another mucosal surface (for example across the nasal, buccal, bronchial or rectal mucosa), transdermally, or by injection (for example intradermal, intraperitoneal, intravenous or intramuscular injection).
- the compounds When the compounds are intended for oral administration, they can be formulated, for example, as tablets, capsules, ovules, granules, pills, lozenges, powders, solutions, emulsions, syrups, elixirs, suspensions, or any other pharmaceutical form suitable for oral administration.
- Oral dosage forms can, if desired, be coated with one or more release delaying coatings to allow the release of the active compound to be controlled or targeted at a particular part of the enteric tract. Tablets and other solid or liquid oral dosage forms can be prepared (e.g. in standard fashion) from the compounds of formula (I) and a pharmaceutically acceptable solubilizer, diluent or carrier.
- solubilizers, diluents or carriers include sugars such as lactose, starches, cellulose and its derivatives, powdered tracaganth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols such as glycerol, propyleneglycol and polyethyleneglycols, alginic acids and alginates, agar, pyrogen free water, isotonic saline, phosphate buffered solutions, and optionally other pharmaceutical excipients such as disintegrants, lubricants, wetting agents such as sodium lauryl sulfate, coloring agents, flavoring agents and preservatives, etc..
- sugars such as lactose, starches, cellulose and its derivatives, powdered tracaganth, malt, gelatin, talc, stearic acid, magnesium stearate, calcium sulfate, vegetable oils, polyols
- Capsules can be of the hard or soft variety and can contain the active compound in solid, liquid or semisolid form. Typically such capsules are formed from gelatine or an equivalent substance and can be coated or uncoated. If it is desired to delay the release of the active compound until the capsule has passed through the stomach and into the intestine, the capsule can be provided with a pH sensitive coating adapted to dissolve at the pH found in the duodenum or ileum. Examples of such coatings include the Eudragits, the uses of which are well known.
- Formulations for injection will usually be made up of the appropriate solubilizers such as detergents which may also include compounds and excipients such as buffering agents to provide an isotonic solution having the correct physiological pH.
- the injectable solutions are typically pyrogen-free and can be provided in sealed vials or ampoules containing a unit dose of compound.
- parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood.
- a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
- suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
- suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
- suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agents.
- Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, poly vinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- a sterile aqueous carrier or parenterally acceptable oil for example polyethylene glycol, poly vinyl pyrrolidone, lecithin, arachis oil or sesame oil.
- the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
- a typical suppository formulation comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.
- composition is in unit dose form such as a tablet or capsule.
- a unit dosage form of the compounds of the invention typically will contain from 0.1% to 99% by weight of the active substance, more usually from 5% to 75% of the active substance.
- a unit dosage form can contain from lmg to lg of the compound, more usually from lOmg to 500mg, for example between 50mg and 400mg, and typically in doses of lOOmg to 200mg.
- Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base.
- the compounds of the invention will be administered in amounts that are effective to provide the. desired therapeutic effect.
- concentrations necessary to provide the desired therapeutic effect will vary according to among other things the precise nature of the disease, the size, weight and age of the patient and the severity of the disease.
- the doses administered will preferably be non-toxic to the patient, although in certain circumstances the severity of the disease under treatment may necessitate administering an amount of compound that causes some signs of toxicity.
- the compounds of the invention will be administered in amounts in the range 0.01 mg/kg to 100 mg/kg body weight, more preferably 0.1 mg/kg to 10 mg/kg body weight and particularly 1 mg/kg to 5 mg/kg body weight.
- the pharmaceutically acceptable compounds of the invention will normally be administered to a subject in a daily dosage regimen.
- a daily dosage regimen for an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.
- a typical daily dosage of the compounds of the invention would be in the range of 70 mg to 700 mg.
- Such a dosage can be administered, for example from two to four times daily.
- Bone reso ⁇ tion inhibitors are those agents known in the art to inhibit the abso ⁇ tion of bone and include, but are not limited to the following classes of compounds: bisphosphonic acids, such as alendronate, cimadronate, clodronate, tiludronate, etidronate, ibandronate, risedronate, piridronate, pamidronate, zoledronate, midronic acid, icandronic acid, and S-12911; selective estrogen receptor modulators (SERMs), such as: raloxifene; HMG CoA reductase inhibitors, such as simvastatin, atorvastatin and cerivastatin; steroid hormones, such as Vitamin D; and polypeptide hormones, such as calc
- Dosage ranges and regimens for bone resorption inhibitors are those which are known in the art.
- a bisphosphonic acid when employed, a daily dosage of 2.5 to 100 mg may be used.
- the components of a combination of the compounds of the present invention and bone reso ⁇ tion inhibitors can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
- the term administering is to be understood as embracing all such regimes of simultaneous or alternating treatment and the scope of combinations of the compounds of this invention and bone reso ⁇ tion inhibitors includes in principle, any combination useful for inhibiting bone loss and building new bone.
- the compounds of this invention increase bone formation and are therefore of value in the treatment of any of these conditions.
- - ⁇ 0 is H, an alkyl group having from 1 to 4 carbon atoms; - X 4 is an optionally substituted benzyl (Bn) group.
- Example 5 Tetraethyl 2-(3-benzyl-4-hydroxynaphthyl')ethenylidene- 1,1- diphosphonate
- Titanium tetrachloride (10.89 g, 57.3 mmol) was added dropwise while stirring to 60 ml of dry tetrahydrofuran. The following compounds were then added sequentially at 5 min intervals while stirring at 0-5°C: 3-benzyl-4- hydroxynaphthaldehyde (5.0 g, 19.1 mmol), then tetraethyl methylenediphosphonate (6.6 g, 22.9 mmol) and finally N-methylmo ⁇ holine (11.58 g, 114.6 mmol). After the addition was completed, the reaction was stirred for 3 h at room temperature then ice water was added.
- Titanium tetrachloride (10.89 g, 57.3 mmol) was added dropwise while stirring to 60 ml of dry tetrahydrofuran. The following compounds were then added sequentially at 5 min intervals while stirring at 0-5°C: 3-benzyl-4-hydroxynaphthaldehyde (5.0 g, 19.1 mmol), then tetraisopropyl methylenediphosphonate (7.9 g, 22.9 mmol) and finally N-methylmo ⁇ holine (11.58 g, 114.6 mmol). After the addition was completed, the reaction was stirred for 3 h at room temperature then ice water was added.
- Example 5 Bone anabolism activity of Compounds of Formula (I); subcutaneous administration
- mice model has previously been characterized with cholesterol synthesis inhibitors such as Simvastatin, see for instance: Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G “Stimulation of bone formation in vitro and in rodents by statins” Science 1999, 286:1946-1949.
- Simvastatin see for instance: Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G “Stimulation of bone formation in vitro and in rodents by statins” Science 1999, 286:1946-1949.
- Test compounds of formula (I) were given at the dose 20 mg/kg by subcutaneous administration (s.c.) in comparison to Dexamethasone (10 mg/kg s.c.) and Simvastatin (10 mg/kg s.c.) and the control group received vehicle alone (propylene glycol, 50 ul). All drugs were given s.c. in the central part of the calvaria on a basis of five administrations per week for 3 weeks. At the end of the study, animals were sacrificed under pentobarbital anesthesia, blood was collected and serum was obtained.
- the femur and calvaria (a flat bone on the cranium) were dissected and frozen. Dry bone weight, ash weight and bone calcium were measured after drying and calcination of the calvaria. Bone phosphorus was quantified by a colorimetric molybdate method.
- the Diphosphonate Ester compounds , 2_and_4 and the vinylic diphosphonic acid compound 5 showed a clear profile of anabolic activity judging from the increase in calvaria weight as compared to femur weight, measured as a control. Both relevant ions, calcium and phosphorus are increased. More specifically, The Diphosphonate Ester compound I increased calvaria weight by +19%, calvaria calcium by +12% and calvaria phosphorus by +20%. In contrast, the non-vinylic Diphosphonic Acid Compound 3 was inactive
- Table 1 Effect of selected compounds of formula (I) on calvaria ash weight and mineral content (calcium and phosphorus) in treated mice, expressed as % change from the control group
- Example 6 Bone anabolism activity of Compound 1 ; oral administration
- mice were administered Compound I orally at doses of 50 and lOOmg/kg for 18 days.
- the metaphysis containing trabecular bone was separated and weighed.
- the content of mineral ions, calcium and phosphorus of trabecular bone were measured by chemical methods, the density of trabecular bone was determined by peripheral Quantitative Computerized Tomography (pQCT) using a Stratec apparatus.
- pQCT Quantitative Computerized Tomography
- Table 2 show that Compound ⁇ increased trabecular bone ash weight and mineral (calcium and phosphorus) content.
- Table 2 Effect of Compound I on femur trabecular ash weight and mineral content in mice
- mice Groups of 12 mice were treated orally with 200 mg/kg of Compound ⁇ for 3 weeks. Bone tissue was fixed, processed and stained for the histomo ⁇ hometric measurement of the number of osteoblasts. Compound ⁇ increased significantly the number of osteoblasts by 31% (p ⁇ 0.05) in the tibia of treated mice.
- test method described above can also be used to determine the activities of other compounds of the formula (I).
- Bone specific alkaline phosphatase was selected for measurement as it is the most important marker which has been correlated with bone formation.
- the results from Table 4 show that Compound I given orally induces bone alkaline phosphatase. This increase in bone alkaline phosphatase occurred without a simultaneous increase in total plasma alkaline phosphatase produced by non-bone tissues, eg liver (data not shown). These data clearly demonstrate that the compounds of formula (I) have a specific activity on osteoblast differentiation leading to bone growth.
- Example 9 Bone anabolic activity of Compound 1 in humans
- Table 5 Changes in Plasma Bone Specific Alkaline Phosphatase (BAP) in a patient orally treated with Compound I at the 50 mg/kg/day dose bid for 3 weeks
- the diphosphonate esters being high lipophilic are very efficiently absorbed when given orally in rodents, primates and in man. For example, as shown in FIG. 1, plasma levels greater than lOOOng/ml were reached and maintained for several hours in Cynomolgus monkeys receiving Compounds 1 and 2 administered orally (25mg/kg) for three weeks. Pharmacokinetic samples were obtained on the last day of compound administration.
- diphosphonates of formula (I) are active for increasing bone cells, as demonstrated by their activity in the following models:
- Compound 1 a typical prototype of compounds of formula (I), was demontrated to have a good toxicity profile in animals and in addition has high oral bioavailability (greater than 30%) and sufficient systemic exposure in man.
- diphosphonates of formula (I) are a new class of bone anabolic agents with potential utility for treating conditions associated with loss of bone mass due to aging or diseases, such as the following:
- bone loss associated with cancer therapies e.g., bone loss associated with the treatment of gonadotropin-releasing hormone agonists for prostate cancer and bone loss associated with chemotherapy for breast cancer, wherein such chemothe ⁇ ay includes, but is not limited to, cyclophosphamide, methotrexate, fluorouracil, paclitaxel, doxorubicin, tamoxifen and combinations thereof
- chemothe ⁇ ay includes, but is not limited to, cyclophosphamide, methotrexate, fluorouracil, paclitaxel, doxorubicin, tamoxifen and combinations thereof
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002212117A AU2002212117A1 (en) | 2000-08-04 | 2001-07-27 | Use of aryl-substituted 1, 1-diphosphonates for the treatment of bone diseases |
KR10-2003-7001509A KR20030043923A (en) | 2000-08-04 | 2001-07-27 | Use of aryl-substituted 1,1-diphosphonates for the treatment of bone disease |
CA002417606A CA2417606A1 (en) | 2000-08-04 | 2001-07-27 | Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
JP2002517041A JP2004505908A (en) | 2000-08-04 | 2001-07-27 | Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
EP01980218A EP1326618A2 (en) | 2000-08-04 | 2001-07-27 | Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0019272.4 | 2000-08-04 | ||
GBGB0019272.4A GB0019272D0 (en) | 2000-08-04 | 2000-08-04 | Pharmaceutical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002011704A2 true WO2002011704A2 (en) | 2002-02-14 |
WO2002011704A3 WO2002011704A3 (en) | 2002-07-18 |
Family
ID=9897063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/008676 WO2002011704A2 (en) | 2000-08-04 | 2001-07-27 | Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1326618A2 (en) |
JP (1) | JP2004505908A (en) |
KR (1) | KR20030043923A (en) |
CN (1) | CN1561219A (en) |
AU (1) | AU2002212117A1 (en) |
CA (1) | CA2417606A1 (en) |
GB (1) | GB0019272D0 (en) |
WO (1) | WO2002011704A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1506208A2 (en) * | 2002-05-11 | 2005-02-16 | Ilex Products, Inc. | 1,1- and 1,2-bisphosphonates as apolipoprotein e modulators |
WO2008128056A1 (en) * | 2004-10-08 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
WO2007109585A3 (en) * | 2006-03-17 | 2008-11-06 | Univ Illinois | Bisphosphonate compounds and methods |
US7745422B2 (en) | 2004-10-08 | 2010-06-29 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
WO2016063297A1 (en) | 2014-10-21 | 2016-04-28 | Council Of Scientific & Industrial Research | Alkylidene phosphonate esters as p-glycoprotein inducers |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2203460A4 (en) * | 2007-04-12 | 2012-03-14 | Univ Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0440809A1 (en) * | 1989-08-18 | 1991-08-14 | Toray Industries, Inc. | Methylenediphosphonic acid compound and anti-inflammatory containing the same as active ingredient |
US5043330A (en) * | 1988-03-31 | 1991-08-27 | Symphar S.A. | Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them |
US5204336A (en) * | 1990-09-13 | 1993-04-20 | Symphar S.A. | Naphthyl-,tetrahydronaphthyl-, and indanyl-substituted G-em-diphosphonates and process of use to treat hyperlipidemia |
EP0603401A1 (en) * | 1992-07-10 | 1994-06-29 | Toray Industries, Inc. | Methanediphosphonate derivative, production thereof, and pharmaceutical use thereof |
EP0845991A2 (en) * | 1995-07-28 | 1998-06-10 | Symphar S.A. | Use of phenol substituted diphosphonates as antineoplastic agents |
US5994329A (en) * | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
-
2000
- 2000-08-04 GB GBGB0019272.4A patent/GB0019272D0/en not_active Ceased
-
2001
- 2001-07-27 CN CNA018150748A patent/CN1561219A/en active Pending
- 2001-07-27 WO PCT/EP2001/008676 patent/WO2002011704A2/en not_active Application Discontinuation
- 2001-07-27 CA CA002417606A patent/CA2417606A1/en not_active Abandoned
- 2001-07-27 JP JP2002517041A patent/JP2004505908A/en not_active Withdrawn
- 2001-07-27 AU AU2002212117A patent/AU2002212117A1/en not_active Abandoned
- 2001-07-27 EP EP01980218A patent/EP1326618A2/en not_active Withdrawn
- 2001-07-27 KR KR10-2003-7001509A patent/KR20030043923A/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5043330A (en) * | 1988-03-31 | 1991-08-27 | Symphar S.A. | Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them |
EP0440809A1 (en) * | 1989-08-18 | 1991-08-14 | Toray Industries, Inc. | Methylenediphosphonic acid compound and anti-inflammatory containing the same as active ingredient |
US5204336A (en) * | 1990-09-13 | 1993-04-20 | Symphar S.A. | Naphthyl-,tetrahydronaphthyl-, and indanyl-substituted G-em-diphosphonates and process of use to treat hyperlipidemia |
EP0603401A1 (en) * | 1992-07-10 | 1994-06-29 | Toray Industries, Inc. | Methanediphosphonate derivative, production thereof, and pharmaceutical use thereof |
EP0845991A2 (en) * | 1995-07-28 | 1998-06-10 | Symphar S.A. | Use of phenol substituted diphosphonates as antineoplastic agents |
US5994329A (en) * | 1997-07-22 | 1999-11-30 | Merck & Co., Inc. | Method for inhibiting bone resorption |
Non-Patent Citations (1)
Title |
---|
NIESOR ERIC J ET AL: "Apomine (SR-45023A) prevents bone metastasis of breast adenocarcinoma cells by a mechanism involving bone anabolism." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 42, March 2001 (2001-03), page 263 XP001026495 92nd Annual Meeting of the American Association for Cancer Research;New Orleans, LA, USA; March 24-28, 2001, March, 2001 ISSN: 0197-016X * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1506208A2 (en) * | 2002-05-11 | 2005-02-16 | Ilex Products, Inc. | 1,1- and 1,2-bisphosphonates as apolipoprotein e modulators |
EP1506208A4 (en) * | 2002-05-11 | 2006-05-24 | Ilex Products Inc | 1,1- and 1,2-bisphosphonates as apolipoprotein e modulators |
WO2008128056A1 (en) * | 2004-10-08 | 2008-10-23 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps |
US7745422B2 (en) | 2004-10-08 | 2010-06-29 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
US8012949B2 (en) | 2004-10-08 | 2011-09-06 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS |
US8071573B2 (en) | 2004-10-08 | 2011-12-06 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases |
WO2007109585A3 (en) * | 2006-03-17 | 2008-11-06 | Univ Illinois | Bisphosphonate compounds and methods |
US7687482B2 (en) | 2006-03-17 | 2010-03-30 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
AU2007226964B2 (en) * | 2006-03-17 | 2012-03-22 | The Board Of Trustees Of The University Of Illinois | Bisphosphonate compounds and methods |
US8882740B2 (en) | 2009-12-23 | 2014-11-11 | Stryker Trauma Gmbh | Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone |
WO2016063297A1 (en) | 2014-10-21 | 2016-04-28 | Council Of Scientific & Industrial Research | Alkylidene phosphonate esters as p-glycoprotein inducers |
US10377781B2 (en) | 2014-10-21 | 2019-08-13 | Council Of Scientific & Industrial Research | Alkylidene phosphonate esters as p-glycoprotein inducers |
Also Published As
Publication number | Publication date |
---|---|
AU2002212117A1 (en) | 2002-02-18 |
EP1326618A2 (en) | 2003-07-16 |
CN1561219A (en) | 2005-01-05 |
WO2002011704A3 (en) | 2002-07-18 |
CA2417606A1 (en) | 2002-02-14 |
JP2004505908A (en) | 2004-02-26 |
GB0019272D0 (en) | 2000-09-27 |
KR20030043923A (en) | 2003-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU723094B2 (en) | Use of phenol substituted diphosphonates as antineoplastic agents | |
US6372728B1 (en) | Formulation for treatment of osteoporosis | |
JP6067466B2 (en) | Bisphosphonic acid for treatment and prevention of osteoporosis | |
RU2006126783A (en) | PHARMACEUTICAL COMPOSITIONS OF BISPHOSPHONATES | |
JP5244917B2 (en) | C2-C5-alkyl-imidazole-bisphosphonates | |
AU4161900A (en) | A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate | |
EP0573604B1 (en) | Methods for the treatment of osteoporosis | |
JP2001253827A (en) | Composition and method for treating osteoporosis | |
WO2002011704A2 (en) | Use of aryl-substituted 1,1-diphosphonates for the treatment of bone diseases | |
EP1551418A1 (en) | Substituted ketophosphonate compounds having bone anabolic activity | |
RU2294203C2 (en) | Method for treatment of osseous disorders | |
Cakarer et al. | Bisphosphonates and bone | |
JP2003529365A (en) | Method for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase | |
US20040043072A1 (en) | Alleviation of upper gastrointestinal irritation | |
EP1328277B1 (en) | Bisphosphonic compounds for strengthening of cortical bone | |
US20080139845A1 (en) | Ibandronate sodium propylene glycol solvate and processes for the preparation thereof | |
EP1397146A2 (en) | Compositions and methods for inhibiting bone resorption | |
JP4692283B2 (en) | Malignant melanoma treatment | |
CZ296694A3 (en) | Phosphonate compounds containing quaternary nitrogen atom and their use in a pharmaceutical preparation for treating abnormal calcium and phosphate metabolism | |
WO2004026243A2 (en) | Therapeutic uses of linear ketophosphonates | |
MX2011013867A (en) | Biophosphonates useful for preventing and treating abnormal bone resorption. | |
AU2005227418A1 (en) | Method for inhibiting bone resorption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002212117 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2417606 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002517041 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037001509 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001980218 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018150748 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037001509 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001980218 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001980218 Country of ref document: EP |